Literature DB >> 32706415

Outcomes of Primary Versus Salvage Surgery for Sinonasal Malignancies: A Population-Based Analysis.

Brandon M Lehrich1, Tyler M Yasaka1, Khodayar Goshtasbi1, Edward C Kuan1.   

Abstract

OBJECTIVES/HYPOTHESIS: There exists a lack of consensus on the optimal sequence of treatment for many sinonasal malignancies (SNMs). This study compares the overall survival (OS) outcomes for primary surgery (PS) versus salvage surgery (SS) in SNM patients across stage, histology, and primary site. STUDY
DESIGN: Retrospective database review.
METHODS: The National Cancer Database was queried for all SNM cases treated with multimodal surgical and nonsurgical therapy between 2004 and 2015. Logistic regression identified predictors of SS. Cox proportional hazards models evaluated predictors of mortality, and Kaplan-Meier log-rank test assessed OS outcomes.
RESULTS: Our SNM cohort consisted of 3,011 patients (PS = 2,804; SS = 207). SS patients had significantly longer postoperative hospital stays (P = .009) and increased rates of 30-day (P < .001) and 90-day mortality (P < .001) compared to PS. On multivariate logistic regression, predictors of undergoing SS included sinonasal undifferentiated carcinoma histology (odds ratio = 2.72; 95% confidence interval [CI]: 1.16-6.66; P = .024). On multivariate Cox proportional hazards analyses among SS patients, late-stage disease (hazard ratio [HR] = 4.80; 95% CI: 1.46-15.8; P = .01) and positive surgical margins (HR = 2.31; 95% CI: 1.29-4.13; P = .005) portended significantly worse OS. In the propensity score-matched cohort controlling for stage and histology, PS had significantly improved OS compared to SS (P = .007). Compared to SS, PS also had improved OS in subgroup analyses for patients with late-stage disease (P = .026) and squamous cell carcinoma histology (P = .006).
CONCLUSIONS: In our SMN cohort, PS resulted in improved OS outcomes compared to SS independent of stage and histology. Consideration may be given to primary surgical resection for SMN whenever feasible, though a targeted, individualized approach is warranted. LEVEL OF EVIDENCE: 3 Laryngoscope, 131:E710-E718, 2021.
© 2020 The American Laryngological, Rhinological and Otological Society, Inc.

Entities:  

Keywords:  National Cancer Database; Sinonasal malignancies; multimodal treatment; salvage surgery; sinonasal recurrence; survival prognosis

Mesh:

Year:  2020        PMID: 32706415     DOI: 10.1002/lary.28925

Source DB:  PubMed          Journal:  Laryngoscope        ISSN: 0023-852X            Impact factor:   3.325


  2 in total

1.  Oncologic outcome of multimodality treatment for sinonasal malignancies: An 18-year experience.

Authors:  Meng-Yu Chen; Xin Wen; Yi Wei; Lin Chen; Zi-Xuan Huang; Tong Lu; Nian-Zhen Zheng; Jian Li; Wei-Ping Wen; Yi-Hui Wen
Journal:  Front Oncol       Date:  2022-09-05       Impact factor: 5.738

2.  Salvage surgery in recurrent sinonasal cancers: Proposal for a prognostic model based on clinicopathologic and treatment-related parameters.

Authors:  Davide Mattavelli; Michele Tomasoni; Marco Ferrari; Alessandra Compagnoni; Alberto Schreiber; Stefano Taboni; Vittorio Rampinelli; Elisa Marazzi; Elena Raffetti; Luca Oscar Redaelli de Zinis; Alberto Deganello; Roberto Maroldi; Paolo Bossi; Cesare Piazza; Piero Nicolai
Journal:  Head Neck       Date:  2022-06-02       Impact factor: 3.821

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.